P/E ratio for Geron (GERN)
P/E ratio as of April 2024 (TTM): -11.0
According to Geron's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.9706. At the end of 2022 the company had a P/E ratio of -6.72.
P/E ratio history for Geron from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -6.72 | 98.36% |
| 2021 | -3.39 | -42.45% |
| 2020 | -5.89 | 55.88% |
| 2019 | -3.78 | -43.33% |
| 2018 | -6.67 | -33.33% |
| 2017 | -10.0 | -13.04% |
| 2016 | -11.5 | -100% |
| 2015 | > 1000 | -2.5754492687525E+18% |
| 2014 | -13.5 | -12.34% |
| 2013 | -15.4 | 525.97% |
| 2012 | -2.47 | 39.38% |
| 2011 | -1.77 | -58.49% |
| 2010 | -4.27 | -34.13% |
| 2009 | -6.48 | 15.91% |
| 2008 | -5.59 | -36.51% |
| 2007 | -8.80 | -43.79% |
| 2006 | -15.7 | 13.52% |
| 2005 | -13.8 | 240.57% |
| 2004 | -4.05 | -58.74% |
| 2003 | -9.82 | 298.11% |
| 2002 | -2.47 | -43.03% |
| 2001 | -4.33 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 15.1 | -237.37% | 🇺🇸 USA |
 Incyte INCY | 27.8 | -353.40% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -15.7 | 42.86% | 🇺🇸 USA |
 Bio-Techne TECH | 39.6 | -461.19% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | -0.3812 | -96.53% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.